Press Release from Paris Regional Medical Center. For more information, click here
Paris Regional Medical Center is proud to offer both bamlanivimab/casirivimab and imdevimab therapy, new monoclonal antibody treatments for eligible positive COVID-19 patients.
What are bamlanivimab/casirivimab and imdevimab or monoclonal antibody treatment?
Bamlanivimab/Casirivimab and imdevimab are monoclonal antibody treatments developed by pharmaceutical companies Eli Lilly and Regeneron Pharmaceuticals to help treat non-hospitalized patients with a mild or moderate case of COVID-19 (SARS-CoV-2). Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful viruses. This therapy is designed to help block the COVID-19 virus and prevent the virus from further infecting healthy cells.
Bamlanivimab/Casirivimab and imdevimab have received emergency use authorization (EUA) from the Food and Drug Administration (FDA) and is now being allocated by the U.S. Department of Health and Human Services (HHS) in partnership with the Texas Department of State Health Services and other state agencies.
Who is a candidate for monoclonal antibody treatment?
Adults and adolescents 12 years of age or older with mild to moderate symptoms who weigh 88 pounds (40 kg) or more, and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.
Patients must meet specific clinical criteria including:
- Lab-confirmed COVID-19 positive test
- Stable enough to not require hospitalization
- Be within 10 days of symptom onset
In addition to meeting the above criteria, patients must also have an order from a provider to receive this treatment.
Who is not a candidate for this treatment?
This treatment will not be considered for patients who are currently hospitalized due to COVID-19, require oxygen therapy for COVID-19, and/or have a known hypersensitivity to bamlanivimab/casirivimab and imdevimab.
How do I qualify for this treatment?
This therapy requires an order from a healthcare provider.
You may:
- Contact your primary care physician (PCP) to make an appointment, OR
- Call our Provider Referral Line (PRL) at 903.737.3232 or visit our Find a Provider feature.
What should I expect?
Your physician’s office will provide steps on how and where you will be receiving your treatment. Treatment is administered intravenously (using IV therapy). Patients receiving treatment at Paris Regional Medical Center will be required to stay for a duration of 2 hours.
Important facts about bamlanivimab
For information on the authorized use of bamlanivimab and mandatory requirements under the Emergency Use Authorization, please review:
Fact Sheet for Patients, Parents and Caregivers (English)
Fact Sheet for Patients, Parents and Caregivers (Spanish)
Important facts about casirivimab and imdevimab
For information on the authorized use of casirivimab and imdevimab and mandatory requirements under the Emergency Use Authorization, please review:
Fact Sheet for Patients, Parents and Caregivers (English)
Fact Sheet for Patients, Parents and Caregivers (Spanish)
